FindTrial
Sign In

To assess the correlation chemotherapy effect on the tumor and in the patient derived organ like creation from pancreatic cancer cells.

Do patient derived organoids predict therapeutic response in pancreatic cancer patients with advanced disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/05/008512
Enrollment
20
Registered
2017-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C25- Malignant neoplasm of pancreas

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with metastatic pancreatic adenocarcinoma with liver metastasis Treatment naive Willing to consent for ultrasound guided core biopsy ECOG PS 0 or 1

Exclusion criteria

Exclusion criteria: Metastasis to CNS PS or general condition does not allow FOLFIRINOX based chemotherapy Refused consent for participation in study Severe medical conditions or illness including HIV HBV HCV infections. Inadequate organ functions. Previously treated with any chemo radio biological immunotherapy.

Design outcomes

Primary

MeasureTime frame
To compare the responses to chemotherapy drugs in metastatic pancreatic cancer patients in vivo radiologically by RECIST criteria) versus in vitro with patient derived organoid.Timepoint: 24 Month—

Secondary

MeasureTime frame
To identify clinico-serological and radiological markers co relating the drug responses with the help of the patient derived organoid. Timepoint: 24 month—

Countries

India

Contacts

Public ContactVikas ostwal

Tata Memorial Hospital

dr.vikas.ostwal@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026